Epigenetics leadership Oryzon Genomics is a clinical-stage biopharmaceutical company with a European leadership position in epigenetics, focusing on personalized medicine for CNS disorders and oncology. This positions the company as a potential partner for collaborators seeking epigenetic targets and biomarker-driven strategies.

Late-stage AML signals Iadademstat in AML has shown promising efficacy signals, including a reported 100% overall response rate in first-line AML at ASH 2025, with further data expected at EHA 2026. This creates opportunities for licensing, co-development, or strategic partnerships with oncology developers and investors.

CNS and ASD focus Vafidemstat targets neuropsychiatric indications across schizophrenia negative symptoms, Borderline Personality Disorder, and autism spectrum disorders with genetically defined subpopulations. This breadth suggests collaboration with pharma focusing on CNS disorders, rare disease programs, and precision medicine initiatives.

Diversified pipeline Beyond LSD1 inhibitors, Oryzon is advancing HDAC6 antagonist ORY-4001 for neurological diseases, indicating potential cross-portfolio licensing, co-development, or in-licensing discussions to broaden partner companies’ epigenetic capabilities.

Strategic funding and partnerships With substantial funding and European Commission engagement, plus active participation in major industry events and a biomarker platform for precision medicine, Oryzon presents multiple avenues for collaboration, including translational research partnerships, strategic investments, and contracted development or commercialization arrangements.